Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF

Phase 2 Terminated 24 enrolled University Hospital, Basel, Switzerland

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the efficacy of a single injection of Canakinumab on AF recurrences within 6 months after electrical cardioversion in patients with persistent AF.

Timeline

Start: 2013-06
Primary completion: 2016-12
Completion: 2016-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Canakinumab	Monoclonal antibody	150 mg	Subcutaneous

Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF

Summary

Timeline

Drugs

Indications